Tuesday, July 20, 2010

OXIS : Review

 

OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress associated with damage from free radical and reactive oxygen species and the related increased inflammation that accompanies oxidative stress. OXIS presently holds the rights to three therapeutic classes of compounds in the treatment of oxidative stress, and has focused commercialization programs in clinical cardiovascular markers, including MPO myeloperoxidase and GPx (glutathione peroxidase), as well as the super potent antioxidant, Ergothioneine, that is planned to be introduced as an over-the-counter nutraceutical supplement. OXIS's customers include leading pharmaceutical companies such as Pfizer, Glaxo Smith Kline and Genzyme and universities such as Baylor College of Medicine, University of Minnesota, Virginia School of Technology, distributors and government laboratories.

OXIS International, Inc. is engaged in the research, development and sale of product that counteract the harmful effect of " Oxidative Stress ". Their product were include therapeutic nutraceutical product, cosmeceutical product and proprietary formulation and clinical product.OXIS primary products incorporate and emphasize the multifaceted “super antioxidant” compound, L-­Ergothioneine (“ERGO”), as a key component .

Oxidative stress represent an imbalance between the production of reactive oxygen species and the biological system's ability to readily detoxifying the reactive intermediate or to repair the resulting damage. All form of life maintain a reducing environment which is preserved by enzymes that maintain the reduced state through a constant input of metabolic energy within their cell. Disturbance in this normal redox state can cause toxic effects through the production of peroxides and free radical that damage all component of cell, including protein, lipid and DNA. 

ERGO is a unique, naturally occurring anti-oxidant/anti-inflammatory agent that is abundant in most plants and animals. ERGO cannot be synthesized by humans and therefore is available only from dietary sources. Oxis was the first company to develop a patented synthetic process for the manufacture of pure ERGO. The proprietary manufacturing process has been approved in North America, Japan, and Western Europe.
Ergothioneine protects the skin from oxidative and DNA damage.   It is an antioxidant, protecting the mitochondrial membrane against oxidation.   It will transfer fatty acids into the mitochondria to help use oxygen efficiently and to produce more energy.  It also protects DNA from the oxidation of guanine.  Ergothioneine reduces TNF-Alpha (Tumor Necrosis Factor), a stress signal cytokine.In other words, product with EGRO also contained with Glutathione, an antioxidant that help protect cells from reactive oxygen species such as free radical and peroxides.

For those who looking for anti-aging supplementary based on plant extract, i think Oxis offered alternative solution with their coming soon product. 
Two product from OXIS as below that have the benefit of "super antioxidant"  will launch on summer 2010: 
  • “Ergo-Pur™”  - ERGO-Pur is a pure form of our highly potent multifaceted antioxidant which we anticipate will be used in some cases in concert with:
  • “Ergo-Plex™” – ERGO-Plex is a combination of ERGO plus other functional nutraceutical ingredients directed at Joint Health.  
More information about OXIS and their products, services as well as current SEC filings may be obtained by visiting http://www.oxisresearch.com/  and http://www.oxis.com/

People who interested with the Oxis updates may join and follow them on http://twitter.com/oxisinc and also at http://www.facebook.com/OxisInc


     
 


    No comments:

    Post a Comment

    Million Thanks for Leaving me a comment!

    LinkWithin

    Related Posts Plugin for WordPress, Blogger...